A recently developed vaccine against the Ebola virus provided 100 percent protection in preliminary trials, showing such promise that the World Health Organization is extending vaccination to “all people at risk.” According to a WHO statement Friday, the VSV-EBOV vaccine was hailed as “highly effective” and could help prevent the spread of the deadly disease in current and future outbreaks. Trials began in March in Guinea, one of the three West African nations rocked in the recent outbreak. More than 4,000 people who came in contact with almost 100 Ebola patients participated in the trial, according to the release. WHO officials said it could take as long as two months to develop more supply. More than 10,000 people have died in Guinea, Sierra Leone, and Liberia since the epidemic began last year.